# A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

> **NCT01436656** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 107 (actual)

## Conditions studied

- Melanoma and Metastatic Colorectal Cancer

## Interventions

- **DRUG:** LGX818

## Key facts

- **NCT ID:** NCT01436656
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-05
- **Primary completion:** 2012-10-01
- **Final completion:** 2022-11-07
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01436656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01436656, "A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01436656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*